At the end of 2022, a new Phase I open-label has started to determine the safety and effectiveness of [212Pb]Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing tumors, including BC patients (NCT05283330) (105). This evidence concerns the gene GRPR and breast cancer.